Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more

Recent & Breaking News (NDAQ:VIR)

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

GlobeNewswire August 29, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire August 25, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire August 23, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire August 4, 2023

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023

GlobeNewswire July 26, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 26, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 24, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 21, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 20, 2023

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

GlobeNewswire July 20, 2023

Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

GlobeNewswire June 29, 2023

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

GlobeNewswire June 24, 2023

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL(TM) Congress 2023

GlobeNewswire June 7, 2023

Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

GlobeNewswire June 5, 2023

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

GlobeNewswire May 17, 2023

Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

GlobeNewswire May 15, 2023

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

GlobeNewswire May 11, 2023

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference

GlobeNewswire May 3, 2023